Phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer.

Trial Profile

Phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil; Mitomycin
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TUXEDO
  • Most Recent Events

    • 06 Jun 2017 Combined results of phases I/II, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 09 Mar 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.
    • 11 Feb 2016 Accrual to date is 31% according to United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top